Last reviewed · How we verify
5-Fluoracil
5-Fluorouracil is a thymidylate synthase inhibitor that disrupts DNA synthesis and function.
5-Fluorouracil is a thymidylate synthase inhibitor that disrupts DNA synthesis and function. Used for Adjuvant treatment of colon cancer, Treatment of breast cancer, Treatment of stomach cancer.
At a glance
| Generic name | 5-Fluoracil |
|---|---|
| Also known as | All Brands |
| Sponsor | Servicio de Salud Metropolitano Sur Oriente |
| Drug class | pyrimidine analog |
| Target | thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
5-Fluorouracil works by inhibiting thymidylate synthase, an enzyme necessary for DNA synthesis. This leads to the disruption of DNA replication and function, ultimately causing cell death in rapidly dividing cancer cells.
Approved indications
- Adjuvant treatment of colon cancer
- Treatment of breast cancer
- Treatment of stomach cancer
Common side effects
- Mucositis
- Diarrhea
- Nausea
- Vomiting
- Fatigue
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer (PHASE2)
- Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (PHASE3)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations (PHASE3)
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 5-Fluoracil CI brief — competitive landscape report
- 5-Fluoracil updates RSS · CI watch RSS
- Servicio de Salud Metropolitano Sur Oriente portfolio CI